{
  "report_rows": [
    {
      "kpi": "Total revenue",
      "prediction": "BEAT",
      "answer": "pred ~$3.27B vs. cons $3.23B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-GAAP diluted EPS",
      "prediction": "BEAT",
      "answer": "pred ~$4.48 vs. cons $4.30",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Non-CF product revenue (CASGEVY + JOURNAVX)",
      "prediction": "BEAT",
      "answer": "pred ~$0.120B vs. cons $0.110B",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "FY26 total revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$13.03B midpoint vs. cons $12.97B (FY26)",
      "confidence": "HIGH"
    },
    {
      "kpi": "FY26 non-CF product revenue guidance",
      "prediction": "UNCHANGED",
      "answer": "guide ~$0.50B minimum vs. cons $0.50B (FY26)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Povetacicept IgAN regulatory timing",
      "prediction": "UNCHANGED",
      "answer": "guide ~November 30, 2026 PDUFA vs. cons November 30, 2026 (2H26)",
      "confidence": "HIGH"
    }
  ],
  "day1_residual_pct": 2.8,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 1.0,
  "day5_path": "FADE",
  "day5_rationale": "The initial ~+2.8% residual reaction to a modest revenue/EPS and non-CF-sales beat should fade toward ~+1.0% over five days because reiterated ~$0.50B FY26 non-CF guidance still requires an approximately ~$0.154B average quarterly non-CF run-rate in 3Q\u20134Q after an estimated ~$0.120B 2Q result, leaving out-period revenue and EPS estimates vulnerable to modest cuts.",
  "day5_confidence": "MEDIUM"
}